Novartis AG has grown revenue 4.5% a year over three years and 2.3% a year over five, with earnings per share compounding at −4.7%. Revenue growth, 3-year annual rate: +4.5% (Drug Manufacturers - General median +6.3%). Revenue growth, 5-year rate: +2.3%, growth has picked up over the last three years. Earnings per share, 3-year rate: −4.7%, earnings lagged revenue: the growth is costing something. Years of annual history on file: 11, FY2015 to FY2025, as filed.

NVSNovartis AG

Healthcare

$143.73+20% 1Y

$143.73

$118.2052 weeks$163.64

Is it growing?

Good

Operating margin widening (+10.5 points). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 good, 2 without data

Margin direction+10.5 points operatingSEC EDGAR · Jun 30, 2025

Trailing-twelve-month operating margin, 34.9% now against 24.4% a year earlier.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NVS growing?

Novartis AG has grown revenue 4.5% a year over three years and 2.3% a year over five, with earnings per share compounding at −4.7%.

+4.5%

Revenue growth, 3-year annual rate · Drug Manufacturers - General median +6.3% · growing slowly · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +2.3%
Revenue growth, 5-year rate · +4.5% over three · growth has picked up over the last three years
Earnings per share, 3-year rate: −4.7%
Earnings per share, 3-year rate · revenue +4.5% · earnings lagged revenue: the growth is costing something
Years of annual history on file: 11
Years of annual history on file · FY2015 to FY2025, as filed